North America Bacteriophage Therapy Market Industry Trends and Forecast to 2034: Segmented by (Type, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
North America · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$35.2 MnPlaceholder estimate
Estimate 2025$40.1 Mn50.5% of the global market
Projected 2034$127.3 Mn 217.6%Adds $87.2 Mn over 9 forecast years
CAGR 2025–203413.7%Faster than 74% of 180 Pharmaceuticals markets here
Key players5Companies profiled
North America is 50.51% of the global market.
Among regions, the largest is North America (this report) at $40.1 Mn.
Armata Pharmaceuticals, Locus Biosciences, Adaptive Phage Therapeutics, BiomX, Intralytix (see all)
Active clinical trials
16 in North AmericaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in North America. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The North America Bacteriophage Therapy Market Analysis Executive Summary
Bacteriophage therapy uses viruses that infect only bacteria to treat infections that antibiotics cannot clear.
Key segments of the bacteriophage Therapy market include type (Natural Phages, Engineered Phages and Phage Cocktails) and application (Chronic Wounds, Respiratory Infections and Urinary Infections).
North America Bacteriophage Therapy market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
North America Bacteriophage Therapy Market Dynamics
Market Growth Drivers
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the bacteriophage Therapy market.
Opportunity
New vaccines, rapid tests and public-private funding for neglected diseases give the bacteriophage Therapy market room to grow, especially in Asia, Africa and Latin America.
Market Restraints
Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the bacteriophage Therapy market.
Competitive Landscape for Bacteriophage Therapy Market in North America
The bacteriophage Therapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Bacteriophage Therapy Market in North America
Bacteriophage Therapy in North America: rules, payment and research
In the countries we cover here, medicines are approved by Health Canada (Canada)[1] and FDA (US)[2]. How care is paid for in these countries: provincial health insurance (Canada)[3] and Medicare and Medicaid (US)[4]. ClinicalTrials.gov lists 16 studies on Bacteriophage Therapy that are recruiting, active or about to start in North America.[5]
[5]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in North America. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for bacteriophage Therapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in North America.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Type
4.2 By Application
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Armata Pharmaceuticals
7.2 Locus Biosciences
7.3 Adaptive Phage Therapeutics
7.4 BiomX
7.5 Intralytix
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The bacteriophage Therapy market can be segmented based on various criteria, including type, application and end user. Here's a breakdown of the market segmentation
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Bacteriophage Therapy market in North America?
Placeholder estimate: about $40.1 Mn in 2025, rising to about $127.3 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Bacteriophage Therapy market in North America growing?
Placeholder estimate: about 13.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Bacteriophage Therapy market report cover?
The report splits the market by type (Natural Phages, Engineered Phages, Phage Cocktails), application (Chronic Wounds, Respiratory Infections, Urinary Infections, Animal Health) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Bacteriophage Therapy market?
Key players include Armata Pharmaceuticals, Locus Biosciences, Adaptive Phage Therapeutics, BiomX and Intralytix.
What is driving the Bacteriophage Therapy market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the bacteriophage Therapy market.
How many clinical trials on Bacteriophage Therapy are running in North America?
16 studies are recruiting, active or about to start in North America, counted across the 2 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in North America. Retrieved 12 Nov 2026.
How much research is published on Bacteriophage Therapy?
PubMed lists 957 papers on Bacteriophage Therapy added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
US
China
Canada
Japan
Germany
UK
Brazil
France
Italy
Ecuador
India
Saudi Arabia
Spain
Mexico
Australia
New Zealand
Russia
South Africa
UAE
Egypt
Hong Kong
Malaysia
Philippines
Singapore
Thailand
Kenya